The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRLM.L Regulatory News (RLM)

  • There is currently no data for RLM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Realm Therapeutics plc

27 Nov 2018 18:28

RNS Number : 6877I
Realm Therapeutics PLC
27 November 2018
 

FORM 8.3

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

RA Capital Management, LLC

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

Peter Kolchinsky (as the managing member of RA Capital Management, LLC)

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Realm Therapeutics plc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

26 November 2018

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

NO

 

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

Ordinary Shares

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

7,181,699

6.16%

(2) Cash-settled derivatives:

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

TOTAL:

7,181,699

6.16%

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

 

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

Ordinary Shares

Sale - 2018 11 26

250,000

GBp 8.00

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

 

 

Date of disclosure:

27 November 2018

Contact name:

Peter Kolchinsky

Telephone number*:

1-617-778-2500

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RETUBRWRWRAAUAA
Date   Source Headline
2nd Nov 20097:00 amRNSDarren Weiss promoted to CFO & Executive Director
15th Sep 20099:47 amRNSHolding(s) in Company
2nd Sep 20092:32 pmRNSHolding(s) in Company
27th Aug 20097:00 amRNSTotal Voting Rights
25th Aug 20094:18 pmRNSHolding(s) in Company
25th Aug 20097:00 amRNSInterim Results
25th Aug 20097:00 amRNSPuriCore New $2.1 Million Facility
5th Aug 20097:00 amRNSTrading Statement
5th Aug 20097:00 amRNSAcquisition and Placing
4th Aug 20097:00 amRNSBlocklisting Interim Review
24th Jul 20094:40 pmRNSSecond Price Monitoring Extn
24th Jul 20094:35 pmRNSPrice Monitoring Extension
10th Jul 20094:40 pmRNSSecond Price Monitoring Extn
10th Jul 20094:35 pmRNSPrice Monitoring Extension
7th Jul 20094:40 pmRNSSecond Price Monitoring Extn
7th Jul 20094:35 pmRNSPrice Monitoring Extension
17th Jun 20097:00 amRNSPresenting at Piper Jaffray European Conference
5th Jun 200911:20 amRNSResult of AGM
28th May 20091:16 pmRNSUS retailer extends use of Sterilox systems
27th May 20097:00 amRNSAnnual Information Update
30th Apr 20095:01 pmRNSHolding(s) in Company
30th Apr 20097:00 amRNSSterilox Effective against Human/Animal Influenza
28th Apr 20097:01 amRNSQ1 Interim Management Statement
28th Apr 20097:00 amRNSFinal Results
17th Feb 200910:45 amRNSHolding(s) in Company
10th Feb 20094:28 pmRNSDirector/PDMR Shareholding
9th Feb 20097:00 amRNSDirector/PDMR Shareholding
6th Feb 200910:27 amRNSHolding(s) in Company
4th Feb 20099:28 amRNSBlocklisting Interim Review
3rd Feb 20099:41 amRNSDirector/PDMR Shareholding
2nd Feb 20097:00 amRNSTrading Statement
2nd Jan 20097:00 amRNSDirector/PDMR Shareholding
29th Dec 20084:34 pmRNSDirector/PDMR Shareholding
19th Dec 20084:43 pmRNSSecond Price Monitoring Extn
19th Dec 20084:36 pmRNSPrice Monitoring Extension
12th Nov 20085:01 pmRNSDirector/PDMR Shareholding
3rd Nov 20087:00 amRNSNotification of PDMR Interest - Option Award
24th Oct 20087:00 amRNSReceives an order from Safeway
13th Oct 20087:01 amRNSBoard and Organisational Changes
13th Oct 20087:00 amRNSInterim Management Statement
1st Oct 20087:00 amRNSRaises $9.74 million
11th Sep 20085:51 pmRNSHolding(s) in Company
4th Sep 20085:51 pmRNSHolding(s) in Company
3rd Sep 20085:26 pmRNSHolding(s) in Company
29th Aug 20082:44 pmRNSPDMR Dealings
29th Aug 20087:00 amRNSTotal Voting Rights
29th Aug 20087:00 amRNSInterim Results
26th Aug 20083:02 pmRNSResult of General Meeting
22nd Aug 20087:00 amRNSResult of Open Offer
4th Aug 20088:27 amRNSBlocklisting six monthly retu

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.